



Partnering at Pace in a Global Health Emergency

April 15, 2021 8 - 9 AM ET



Moderator:
Edward Jones
Houston Methodist
Research Institute



Phil Clare
University of Oxford



Adam Stoten
Oxford University Innovation




Strengthening
University-Industry
Partnerships

TECH SUPPORT

Having technical problems?

- Look for the Tech Q&A doc in chat on the right side of your screen. Or email info@uidp.net.
- If the session shuts down due to connection issues, do NOT close the Attendee Hub window. The room will reopen just a couple of minutes.




how to PARTICIPATE

Live Chat and Q&A

At the right of your screen


- Chat with one another
- Submit questions using the Q&A



how to PARTICIPATE

Handouts and Recordings

- Download available handouts from the Session Content tab on the bottom of your screen.
- Session recordings will be posted in the Attendee Hub. You will be notified via email when they are available at uidp.org.





Strengthening
University-Industry
Partnerships




Strengthening
University-Industry
Partnerships

Disclaimer

UIDP materials, which include publications, webinars, videos, and presentations, reflect an amalgamation of the experiences and knowledge of those who participate in UIDP activities. The views and opinions expressed in UIDP materials do not necessarily reflect the official policy or position of any individual organization or the UIDP. At no time should any UIDP materials be used as a replacement for an individual organization's policy, procedures, or legal counsel. UIDP is not a lobbying organization and UIDP materials are not intended to be used to influence government decisions.

Innovating in a Pandemic...



...or what we did when
we were home-working

Dr Adam Stoten & Dr Phil Clare
Oxford University Innovation Ltd & The University of Oxford


Who we are and what we do

- Deputy Director, Research Services (University)
- Chief Operating Officer, Oxford University Innovation Ltd (Technology Transfer Office)
- We work together to agree policy and act together in matters of Intellectual Property and its commercialisation



Contents

- Chapter 1 – Early days – everyone wants to do something! (Sensyne Health)
 - Developing policy at speed
- Chapter 2 – Getting things into use at top speed (OxSED)
 - Startup to exit in 6 months
- Chapter 3 – Vaccines (Oxford AstraZeneca)
 - Nothing else is more important
- Lessons learned



Early days

- Starting to realise the severity of the situation
- Identification of multiple challenges
- People and companies gathering to look for solutions
- University has people, IP, data that can potentially be useful



Requests for IP in a Pandemic

- “We have an idea to tackle the particular challenges facing pregnant women with Covid, but we need your data”
- “We don’t want to make a profit, but we need to get onto this tomorrow.”
- Discussions were ongoing over a exclusive commercial licence to another party




Decision

- Grant the request for non-exclusive access on limited terms
- Regretfully inform third party that their licence would be non-exclusive (but cheaper)
- Help enquirer get on with developing their solution at speed
- ... quickly realise that this wouldn't be the first request and decide to develop policy guidelines for future cases



Expedited access for COVID-19 related IP


1. OU and OUI will expedite access to Oxford IP to enable global deployment at scale of associated products and services to address the COVID-19 pandemic
 2. The default approach...will be to offer non-exclusive, royalty-free licences to support free of charge, at-cost or cost + limited margin supply as appropriate...for the duration of the pandemic, as defined by the WHO
 3. Licence terms for supplying downstream (post-pandemic) commercial markets will be the subject of a separate agreement
 4. The grant to a Licensee of access to IP under (1) does not guarantee it will be granted downstream commercial rights
 5. [Licences for post-pandemic activity] will carry appropriate financial terms to allow the University to reinvest proceeds in research and teaching.
- 

What happened next?





Self-monitoring of blood pressure during pregnancy



FREE to the NHS until May 2021

[Find out more](#)

The Blood Pressure management system *BPm-Health* allows pregnant women to self-monitor blood pressure during pregnancy and enables healthcare professionals to provide remote care for mums-to-be.



The need for safe remote monitoring during the COVID-19 pandemic

There has been an increasing recognition of the benefits from self-monitoring of blood pressure ('BP') during pregnancy - [see references below](#). The COVID-19 outbreak is now increasing the need for healthcare professionals to advocate BP self-monitoring to reduce face-to-face consultations for pregnant and postnatal women whilst maintaining care for the woman and her baby.

Chapter 2 – the need for a test

- It was quickly realised that a fast, cheap diagnostic test was going to be one of the key requirements for getting out of the pandemic
- OSCAR - Oxford Suzhou Centre for Advanced Research
- Invention by both Oxford and local inventors
- Complex Background
- Urgency enabled swift completion of incorporation
- Created as a Social Enterprise



What happened next?



Oxsed RaViD Direct SARS-COV-2 Test

CE

*In-vitro diagnostic test for the detection of
Coronavirus (SARS-CoV-2)*

Point-of-care test kit

For professional use only

For use with Product code RaViD-Ctrl-01 and RaViD-Acce-01

REF RaViD-OQ-01

IVD




Oxford MESTar Ltd.
Magdalen Centre Oxford Science Park Oxford,
OX4 4GA United Kingdom

Website: <http://www.oxford-mestar.com> Made in the UK

LOT GD200928

2021/03/26



Prenetics Acquires Oxsed, Oxford University Spin-out to Scale Rapid COVID-19 Test Globally. Rapid Airport Testing has begun in Heathrow with Trials in Hong Kong International Airport.

NEWS PROVIDED BY

[Prenetics](#) →

Oct 30, 2020, 04:22 ET

SHARE THIS ARTICLE



- *The Oxsed RaViD Direct test kit is highly accurate at 92% - 100%¹ sensitivity, and provides a scalable and low-cost COVID-19 test which can be performed anywhere. Results in 15-30 minutes*
- *The acquisition will accelerate global access and availability at reasonable cost, particularly for Low- and Middle-Income Countries*
- *Oxsd has received regulatory approvals with MHRA in the UK (FDA Equivalent) and CE Mark in the EU*

OXFORD, United Kingdom, Oct. 30, 2020 /PRNewswire/ -- DNAFit Life Sciences Limited ("DNAFit"), a wholly owned UK entity of Hong Kong based Prenetics Limited ("Prenetics"), has acquired Oxsed, a social venture company which has developed a rapid COVID-19 testing platform based on research from Oxford University.

Under the terms of the agreement, DNAFit and Prenetics have acquired exclusive global rights to the Oxsed technology. Prenetics will work together with the Oxsed team on further R&D efforts to fight the global pandemic. Funds received through the acquisition and access to Prenetics global network of resources will greatly accelerate Oxsed's mission to provide rapid COVID-19 testing globally. Under the terms of the acquisition, Oxsed will maintain its focus on prioritising low- and middle-income countries.

Taking Heathrow Airport to the Skies!

LAMP testing at London's busiest airport.




Tuesday 20th October, 2020 marked a major milestone in the fight against Covid. New pre-departure facilities at London Heathrow terminal 2 and terminal 5 will process LAMP tests for departing passengers.

The industry-leading testing facilities, a UK first, were a critical step in the sector's recovery, restoring traveller confidence and re-opening routes from the UK to the rest of the world.


Chapter 3 – the Big One

- “Our Vaccine looks promising. If it works, we need to make sure it is cheap and global.”
- Multiple Challenges:
 - Global trials chasing the outbreak
 - Developing manufacturing processes
 - Assembling the IP
 - Finding a like-minded partner
 - Funding the work
 - All at the same time



Success Factors

- Leadership from the top
- Sense of urgency – “Nothing is more Important”
- Partner with shared values of commitment to affordable global access
- Sharing of resources and knowledge long before anything is signed
- Recognising what has to be dealt with now, and what can be left
- Understanding each others’ sense of risk



What happened next?



A remarkable trajectory

- 26th April: Term sheet negotiations commence with AZ
 - 29th April: Term sheet signed with AZ (OU/AZ PR)
 - 17th May: Full licence and collaboration agreement signed.
 - 21st May: AZ announce \$1.2b deal with BARDA for US development and supply
 - 4th June: AZ announces deals with CEPI, Gavi Alliance and Serum Institute of India for 1b doses, 400m by end of 2020
 - 21st June: AZ announces deal with Europe's Inclusive Vaccine Alliance to supply 400m doses starting end of 2020
 - 23rd November – Phase III interim efficacy results announced
 - 31st December ...
- 



Medicines & Healthcare products
Regulatory Agency



**The COVID-19 vaccine developed by
Oxford University/AstraZeneca has
been approved for use in the UK**

COVID-19 Vaccine AstraZeneca
solution for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

Intramuscular use

10 multidose vials
(10 doses per vial - 0.5 ml per dose)



COVID-19 Vaccine AstraZeneca

solution for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

10 multidose vials
(10 doses per vial - 0.5 ml per dose)

5 ml



COVID-19 Vaccine AstraZeneca

solution for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

10 multidose vials
(10 doses per vial - 0.5 ml per dose)

5 ml

LOT
EXP
PC
BN



Emirates
Sky Cargo

COVAX

CEPI Gavi

unicef

Eyevek

What did the Crisis give us?

- Commonality of Purpose
- Increased Goodwill
- Clear sense of Priority
- Changed risk equation



Lessons Learned

- Compressing things into one tenth of the usual timescale means leaving some things to later on trust
 - (but you do have to deal with them later)
- Risks are acute, and you don't have much time to think before you act
- You need to rely on good partners to be good at the things they are good at
- Public Benefit mission of the University comes to the fore, and brings clarity to decision making
- Have a core group of experienced people to make decisions together and challenge each other (and be available all the time).

Thankyou & Questions



Please submit your questions using the questions tab.

Session Chat



Chat



Q&A

M Monique Brown

What's the benefit of changing the check-in process?

M Megan Lau

I think the contactless check-in will be a great way to make our attendees feel more comfortable during in-person events 😊



D Doug Brashear

I can't wait to use these new features for my next event!

K Katrina Tanner

I've noticed the same trends as an event attendee. It's wonderful to learn how event planners are staying current.



C Chris McAndrews

Same!

T Trevor Lynn

Does anyone want to connect after the session to discuss what we learned?



C Casey Hartnett

I'm interested



COVID-19, Graduate Students, and Industry Projects

April 15, 2021 | 9:30 - 10:30 AM ET



Moderator:
Rick Tankersley
University of North Carolina
at Charlotte



Jarrett Ellis
Georgia Tech



Chris Feuerstein
L3Harris Technologies



Stacey Shirk
Cornell



Barclay Satterfield
Eastman Chemical
Company



Strengthening
University-Industry
Partnerships

THANK YOU!



- Did you enjoy the session? Rate it in the Attendee Hub!
- You'll receive a survey via email about UIDPVirtual at the end of the week. Please give us your feedback.



Strengthening
University-Industry
Partnerships